Created by Roy Schwartz
Retina specialist updates on clinical guidelines, translational research, imaging, and AI diagnostics
Explore the latest content tracked by Retina Expert Brief
The infographic summarizes efficacy and safety data for high-dose intravitreal aflibercept 8 mg in treatment-naïve neovascular AMD, offering retina specialists key visual and anatomic outcomes to evaluate for extended dosing strategies.
Anti-VEGF-resistant subretinal fluid in AMD is associated with better vision. One key hypothesis ties this to RPE and choriocapillaris damage...
Brolucizumab outperformed panretinal laser photocoagulation for proliferative diabetic retinopathy vision outcomes at week 54 in the CONDOR trial.
-...
AI-based analysis of fundus images enables standardized and reproducible quantification of retinal vascular features, offering consistent metrics that support integration into diagnostic workflows for retina specialists.
This extension study evaluates the long-term efficacy and safety of suprachoroidal triamcinolone acetonide (CLS-TA) in patients with macular oedema, offering critical data on sustained steroid delivery for retinal edema management.
ARVO 2026 data from Cleveland Clinic reveal clear demographic stratification in rhegmatogenous retinal detachment risk after intravitreal injection,...
Indian DME guidelines endorse macular laser, anti-VEGF agents, and intravitreal steroids as core options.
Interpretable machine learning models predict functional visual outcomes by incorporating retinal vascular physiology, specifically how age-related...
Priglinger highlights a pivotal shift: ILM flaps may enable closure without gas or positioning.
Dual Swin U-Net models advance precise segmentation of diabetic retinopathy lesions on imaging. This supports enhanced lesion detection during regular...
Anti-VEGF therapies have transformed management of macular neovascularization and retinal vascular disorders.
Key anatomic effects include clear...
Intravitreal corticosteroids remain an important therapeutic option in inflammation-driven macular edema. This report details the anatomical and...
IZERVAY monthly dosing continued reducing GA lesion growth through 3.5 years, with earlier treatment yielding greater retinal protection.
MCO-010 delivers sustained ~3-line visual gains at 3 years in advanced RP, contrasting the expected 1-line natural-history loss, by targeting bipolar...
Chhablani stresses that cysts with retinal thinning favor MacTel while thickening suggests CME.